News

KalVista's breakthrough drug wins FDA approval after delay
KalVista's journey to FDA approval wasn't smooth sailing, with an unexpected delay and alleged behind-the-scenes drama at the ...
After delay, Kalvista wins FDA OK for drug to treat rare swelling disorder
The company had blamed FDA "resource constraints" for the delay, while a rival drug for hereditary angioedema received an ...
US FDA approves KalVista's oral swelling disorder drug, shares rise
KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug, the first on-demand oral ...
US FDA approves KalVista Pharma's swelling disorder drug, shares rise
KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug, the first on-demand oral ...
GlobalData on MSN20h
FDA approves KalVista’s Ekterly for hereditary angioedema
The US Food and Drug Administration (FDA) has approved KalVista Pharmaceuticals' Ekterly (sebetralstat) as the first and only ...
Fierce Pharma20h
KalVista bounces back from FDA delay with approval for oral rare disease med Ekterly
After facing an unexpected regulatory delay last month, KalVista Pharmaceuticals has leapt into the commercial realm with the ...
pharmaphorum22h
KalVista bags FDA approval for delayed oral HAE drug
KalVista Pharma has finally received FDA approval for its oral kallikrein inhibitor sebetralstat, becoming the first ...
Kalkine Media17h
FDA Clears First Oral HAE Treatment S&P 500 Focus Turns to KalVista
KalVista Pharmaceuticals Inc, a clinical-stage pharmaceutical company listed on the S&P 500, has achieved a significant ...
Orsini Selected as Specialty Pharmacy Partner for KalVista's EKTERLY® (sebetralstat)
Orsini, a leader in rare disease pharmacy solutions, has been chosen by KalVista Pharmaceuticals as a specialty pharmacy ...
KalVista stock soars after FDA approves first oral HAE treatment
Investing.com -- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) stock surged 19% after the company announced FDA approval of EKTERLY (sebetralstat), the first and only oral on-demand treatment for ...
BioSpace21h
KalVista Wins OK for First On-Demand Hereditary Angioedema Pill
Ekterly’s road to approval was not a smooth one. Last month, the FDA informed KalVista it would not meet its PDUFA date due ...
KalVista Pharmaceuticals Shares Rise on FDA Approval of Hereditary Angioedema Drug
KalVista Pharmaceuticals shares jumped in premarket trading Monday after the company said it has received regulatory approval for its treatment of hereditary angioedema. Shares traded 20% higher ahead ...